Cubist court loss makes for a rocky start to merger with Merck

Monday's news that Cubist Pharmaceuticals would be bought by drug giant Merck in a $9.5 billion deal — the biggest biotech acquisition since Sanofi bought Genzyme for $20 billion in 2011 — didn't last long before it hit a snag...